Centessa Pharmaceuticals plc
CNTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | 0.16 | 0.03 | -0.00 |
| FCF Yield | -7.41% | -20.97% | -69.66% | -13.45% |
| EV / EBITDA | -7.44 | -4.37 | 0.16 | -3.55 |
| Quality | ||||
| ROIC | -38.75% | -45.79% | -52.11% | -61.96% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 1.06 | 0.93 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 11.48% | 20.41% | -47.94% | -1,182.48% |
| Safety | ||||
| Net Debt / EBITDA | 1.20 | 0.26 | 1.55 | 3.73 |
| Interest Coverage | -19.93 | -17.29 | -29.17 | -147.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 2,085.08 | 0.00 | 0.00 |